

# Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization: results from the randomized EXCEL trial

Daniel J.F.M. Thuijs<sup>1\*</sup>, Milan Milojevic<sup>1</sup>, Gregg W. Stone<sup>2,3</sup>, John D. Puskas<sup>4</sup>, Patrick W. Serruys<sup>5</sup>, Joseph F. Sabik 3rd<sup>6</sup>, Ovidiu Dressler<sup>3</sup>, Aaron Crowley<sup>3</sup>, Stuart J. Head<sup>1</sup>, and A. Pieter Kappetein<sup>1</sup>

<sup>1</sup>Department of Cardiothoracic Surgery, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands; <sup>2</sup>Division of Cardiology, New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA; <sup>3</sup>Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA; <sup>4</sup>Department of Cardiovascular Surgery, Mount Sinai Heart at Mount Saint Luke's, New York, NY, USA; <sup>5</sup>Department of Cardiology, Imperial College London, London, UK; and <sup>6</sup>Department of Surgery, UH Cleveland Medical Center, Cleveland, OH, USA

Received 24 July 2019; revised 20 October 2019; accepted 24 October 2019

## Aim

To evaluate the impact of left ventricular ejection fraction (LVEF) on 3-year outcomes in patients with left main coronary artery disease (LMCAD) undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in the EXCEL trial.

## Methods and results

The EXCEL trial randomized patients with LMCAD to PCI with everolimus-eluting stents ( $n = 948$ ) or CABG ( $n = 957$ ). Among 1804 patients with known baseline LVEF, 74 (4.1%) had LVEF <40% [heart failure with reduced ejection fraction (HFrEF)], 152 (8.4%) LVEF 40–49% [heart failure with mid-range ejection fraction (HFmrEF)] and 1578 (87.5%) LVEF  $\geq 50\%$  (heart failure with preserved ejection fraction). Patients with HFrEF vs. HFmrEF vs. preserved LVEF experienced a longer postoperative hospital stay (9.0 vs. 7.0 vs. 6.0 days,  $P = 0.02$ ) with greater peri-procedural complications after CABG, while hospital stay after PCI was unaffected by LVEF (1.5 vs. 2.0 vs. 1.0 days,  $P = 0.20$ ). The composite primary endpoint of death, stroke, or myocardial infarction at 3 years was 29.3% (PCI) vs. 27.6% (CABG) in patients with HFrEF, 16.2% vs. 15.0% in patients with HFmrEF, and 14.5% vs. 14.6% in those with preserved LVEF, respectively ( $P_{\text{interaction}} = 0.90$ ). Smoothing spline analysis demonstrated that the 3-year risk of all-cause death increased when LVEF decreased, both in patients undergoing CABG and PCI.

## Conclusion

In the EXCEL trial, the composite rate of death, stroke or myocardial infarction at 3 years was significantly higher in patients with HFrEF compared with HFmrEF or preserved LVEF, driven by an increased rate of all-cause death. No significant differences after PCI vs. CABG were observed among patients with HFrEF, HFmrEF and preserved LVEF. Longer-term follow-up could provide important insights on differences in clinical outcomes that might emerge over time.

Clinical Trial Registration: ClinicalTrials.gov ID NCT01205776.

## Keywords

Coronary artery bypass grafting • Percutaneous coronary intervention • Left main coronary artery disease • Left ventricular ejection fraction • Left ventricular function • Heart failure with reduced ejection fraction

\*Corresponding author. Department of Cardiothoracic Surgery, Erasmus MC, University Medical Centre, Dr. Molewaterplein 40, 3015GD, P.O. Box 2040, Rotterdam, 3000 CA, The Netherlands. Tel: +31 10 7038341, Email: d.thuijs@erasmusmc.nl

## Introduction

Coronary artery bypass surgery is generally recommended for patients with extensive multivessel coronary artery disease (CAD) and severely impaired left ventricular ejection fraction (LVEF) (<35%).<sup>1,2</sup> However, whether coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) is preferred in patients with left main CAD (LMCAD) and impaired LVEF (<50%) is unclear. Whereas randomized trials of patients with impaired LVEF undergoing CABG vs. medical therapy have been performed,<sup>3</sup> most trials comparing PCI with CABG have excluded patients with severely impaired LVEF ( $\leq 35\%$ ). Insights related to myocardial revascularization in patients with impaired LVEF are thus mainly limited to observational studies. A recent systematic review of mainly observational studies ( $n = 16\,191$ ), compared myocardial revascularization with medical therapy and reported an overall survival benefit of CABG over PCI in 8782 patients with LVEF  $\leq 40\%$  [hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.75–0.90].<sup>4</sup> However, the results varied widely between the individual studies ( $I^2 = 47\%$ ), possibly in part because follow-up ranged from 12–180 months. Moreover, only a limited number of patients with LMCAD and impaired LVEF was included in the analysis.

In the EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial, PCI with drug-eluting stents was shown to be an acceptable alternative to CABG in selected patients with LMCAD at 3-year follow-up.<sup>5–7</sup> The current pre-specified EXCEL sub-study aims to estimate the impact of LVEF, defined according to the European Society of Cardiology heart failure terminology,<sup>8</sup> on 3-year outcomes and evaluates differences in treatment effect of PCI with everolimus-eluting stents vs. CABG according to LVEF in patients with LMCAD in the EXCEL trial.

## Methods

### Study design

The design of the EXCEL trial and the main outcomes have been reported previously.<sup>9,10</sup> In brief, 1905 patients with LMCAD and a site-determined SYNTAX score of  $\leq 32$  were randomized to PCI with everolimus-eluting stents ( $n = 948$ ) and CABG ( $n = 957$ ). Among those, baseline data on LVEF were available for 1804 patients (94.7%) and were assessed within 14 days after randomization. In 226 out of 1804 patients (12.5%) LVEF was <50%. These 226 patients were classified according to the European Society of Cardiology heart failure terminology; heart failure with reduced ejection fraction (HFrEF; LVEF <40%) and heart failure with mid-range ejection fraction (HFmrEF; LVEF 40–49%). The HFrEF group consisted of 74 patients, and of those 43 were randomized to PCI and 31 to CABG. There were 152 patients in the HFmrEF group, of which 68 were randomized to PCI and 84 to CABG. LVEF was preserved ( $\geq 50\%$ ) in 1578 out of 1804 patients (87.5%), of whom 782 were randomized to PCI and 796 to CABG. The aim of the present pre-specified analysis was to evaluate the association of LVEF on 3-year clinical outcomes among patients with LMCAD undergoing PCI or CABG.

All patients reached 3-year follow-up at the time of this post-hoc analysis. An independent clinical events committee monitored and adjudicated adverse events. Informed consent was signed by all patients

prior to randomization. The EXCEL trial complies with the Declaration of Helsinki and is registered at ClinicalTrials.gov (NCT01205776).

### Endpoints

The primary endpoint consisted of the composite rate of all-cause death, stroke, or myocardial infarction (MI),<sup>11</sup> at 3 years in subgroups of patients with HFrEF, HFmrEF and preserved LVEF, randomized to either PCI or CABG. Secondary powered endpoints included the primary endpoint measure at 30 days and the composite rate of all-cause death, stroke, MI, or ischaemia-driven revascularization at 3 years in subgroup of patients with HFrEF, HFmrEF and preserved LVEF, randomized to PCI or CABG. Additional endpoints consisted of the individual components of the primary and secondary endpoints at 3 years and 30 days.<sup>9,10</sup>

### Statistical analyses

All analyses were performed according to the intention-to-treat principle. Discrete variables were expressed as percentages with frequencies and compared with the  $\chi^2$  test or Fisher exact test when the expected frequency in any cell was <5. Continuous variables were summarized as mean  $\pm$  standard deviation and were compared by independent samples *t*-test if normally distributed, or the Wilcoxon rank-sum test when non-normally distributed. Event rates up to 3 years were estimated according to the Kaplan–Meier method, and differences between baseline LVEF subgroups (HFrEF, HFmrEF, and preserved), and PCI vs. CABG, were assessed using the log-rank test. Any differences in baseline characteristics between subgroups of patients with HFrEF, HFmrEF and preserved LVEF were adjusted using a multivariable Cox proportional hazard model, correcting for pre-specified important clinical and statistical variables. The association of LVEF as a continuous variable on the 3-year hazard of all-cause death was analysed by smoothing spline analysis with a linear Cox proportional hazards regression model. Baseline characteristics of patients with and without known baseline LVEF were compared to check for potential attrition bias. All reported *P*-values are 2-sided, and  $P < 0.05$  was considered to be statistically significant. Statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC, USA).

## Results

### Baseline characteristics

The baseline characteristics of the overall cohort of patients classified as HFrEF ( $n = 74$ ), HFmrEF ( $n = 152$ ) and those with preserved LVEF ( $n = 1578$ ) are provided in *Table 1*. LVEF was assessed by cardiac ultrasound in 1051 patients (58.3%) and contrast left ventriculography in 715 patients (39.6%). Magnetic resonance or nuclear imaging were used in 38 patients (2.1%). Mean LVEF was 31.6% vs. 43.6% vs. 59.6% in patients with HFrEF vs. HFmrEF vs. preserved LVEF, respectively ( $P = < 0.001$ ). Patients with HFrEF and HFmrEF vs. preserved LVEF had a significantly worse cardiovascular risk profile and had a higher pre-operative risk reflected by increased predicted risk of mortality STS risk scores (1.11 vs. 0.96 vs. 0.86, respectively;  $P = 0.02$ ). More patients with HFrEF had a high SYNTAX score ( $\geq 33$ , core laboratory analysis) compared to those with HFmrEF and preserved

**Table 1** Baseline characteristics according to left ventricular ejection fraction

| Characteristics % (n/N)                                   | LVEF <40%<br>(HF <sub>r</sub> EF) (n = 74) | LVEF 40–49%<br>(HF <sub>mr</sub> EF) (n = 152) | Preserved LVEF ≥50%<br>(n = 1578) | P-value |
|---|--|--|-----------------------------------|---------|
| Age (years)   | 67.0 ± 9.3                                 | 66.7 ± 9.3                                     | 65.9 ± 9.6                        | 0.42    |
| Female sex  | 21/74 (28.4)                               | 20/152 (13.2)                                  | 380/1578 (24.1)                   | 0.006   |
| LVEF (%)  | 31.6 ± 4.2                                 | 43.6 ± 2.6                                     | 59.6 ± 6.6                        | <0.001  |
| CAD risk factors  |  |  |                                   |         |
| Hypertension <sup>a</sup>                                 | 54/74 (73.0)                               | 112/152 (73.7)                                 | 1169/1578 (74.1)                  | 0.97    |
| Hyperlipidaemia   | 45/74 (60.8)                               | 100/151 (66.2)                                 | 1116/1577 (70.8)                  | 0.11    |
| Diabetes mellitus <sup>a</sup>                            | 24/74 (32.4)                               | 57/152 (37.5)                                  | 449/1578 (28.5)                   | 0.05    |
| Current or former smoker                                  | 53/74 (71.6)                               | 103/151 (68.2)                                 | 962/1566 (61.4)                   | 0.06    |
| Family history of CAD                                     | 45/64 (70.3)                               | 92/125 (73.6)                                  | 868/1323 (65.6)                   | 0.16    |
| NYHA class, known   | 23/74 (31.1)                               | 23/152 (15.1)                                  | 73/1573 (4.6)                     | <0.001  |
| I   | 4/74 (5.4)                                 | 3/152 (2.0)                                    | 16/1573 (1.0)                     | 0.003   |
| II  | 6/74 (8.1)                                 | 15/152 (9.9)                                   | 33/1573 (2.1)                     | <0.001  |
| III   | 12/74 (16.2)                               | 5/152 (3.3)                                    | 23/1573 (1.5)                     | <0.001  |
| IV  | 1/74 (1.4)                                 | 0/152 (0.0)                                    | 2/1573 (0.1)                      | 0.04    |
| Pre-operative risk factors                                |  |  |                                   |         |
| History of stroke   | 6/74 (8.1)                                 | 8/152 (5.3)                                    | 50/1577 (3.2)                     | 0.04    |
| History of TIA  | 2/74 (2.7)                                 | 4/151 (2.6)                                    | 47/1569 (3.0)                     | 0.96    |
| Recent myocardial infarction <sup>b</sup>                 | 18/74 (24.3)                               | 34/151 (22.5)                                  | 219/1574 (13.9)                   | 0.001   |
| Chronic kidney disease <sup>c</sup>                       | 24/73 (32.9)                               | 39/149 (26.2)                                  | 231/1550 (14.9)                   | <0.001  |
| Dialysis  | 0/74 (0.0)                                 | 2/152 (1.3)                                    | 3/1578 (0.2)                      | 0.04    |
| Peripheral vascular disease                               | 14/72 (19.4)                               | 23/152 (15.1)                                  | 133/1572 (8.5)                    | 0.004   |
| Chronic obstructive pulmonary disease                     | 14/74 (18.9)                               | 17/152 (11.2)                                  | 113/1575 (7.2)                    | 0.004   |
| History of carotid artery disease                         | 13/74 (17.6)                               | 12/150 (8.0)                                   | 125/1574 (7.9)                    | 0.01    |
| Body mass index (kg/m <sup>2</sup> )                      | 28.9 ± 6.4                                 | 28.7 ± 4.9                                     | 28.7 ± 4.9                        | 0.93    |
| < 20: cachectic   | 2/74 (2.7)                                 | 2/152 (1.3)                                    | 24/1578 (1.52)                    | 0.52    |
| > 30: obese   | 25/74 (33.8)                               | 47/152 (30.9)                                  | 514/1578 (32.6)                   | 0.85    |
| History of anaemia <sup>d</sup>                           | 8/74 (10.8)                                | 23/152 (15.1)                                  | 146/1572 (9.3)                    | 0.07    |
| Lesions per patient                                       | 2.7 ± 1.5 (42)                             | 2.9 ± 1.5 (66)                                 | 2.5 ± 1.3 (773)                   | 0.051   |
| Diffuse disease or small vessels                          | 4/73 (5.5)                                 | 18/146 (12.3)                                  | 85/1555 (5.5)                     | 0.004   |
| Critical pre-operative state <sup>e</sup> STS risk scores |  |  |                                   |         |
| PROM score  | 1.11 ± 1.0                                 | 0.96 ± 0.93                                    | 0.86 ± 0.78                       | 0.02    |
| Stroke score  | 0.97 ± 0.82                                | 0.82 ± 0.61                                    | 0.75 ± 0.56                       | 0.004   |
| Reop. score   | 4.00 ± 1.63                                | 3.64 ± 1.41                                    | 3.51 ± 1.34                       | 0.007   |
| SYNTAX score (site-assessed)                              | 21.0 ± 5.7                                 | 22.4 ± 5.7                                     | 20.4 ± 6.2 (1576)                 | 0.004   |
| Low (≤22)   | 41/74 (55.4)                               | 77/152 (50.7)                                  | 967/1576 (61.4)                   | 0.03    |
| Intermediate (23–32)                                      | 33/74 (44.6)                               | 75/152 (49.3)                                  | 609/1576 (38.6)                   | 0.03    |
| High (≥33)  | 0/74 (0.0)                                 | 0/152 (0.0)                                    | 0/1576 (0.0)                      | –       |
| SYNTAX score (core laboratory-assessed)                   | 28.4 ± 9.7                                 | 27.6 ± 9.2                                     | 26.3 ± 9.3 (1526)                 | 0.06    |
| Low (≤22)   | 24/72 (33.3)                               | 37/144 (25.7)                                  | 563/1526 (36.9)                   | 0.03    |
| Intermediate (23–32)                                      | 21/72 (29.2)                               | 76/144 (52.8)                                  | 600/1526 (39.3)                   | 0.001   |
| High (≥33)  | 27/72 (37.5)                               | 31/144 (21.5)                                  | 363/1526 (23.8)                   | 0.021   |

Values are mean ± standard deviation, or n (%).

CAD, coronary artery disease; HF<sub>mr</sub>EF, heart failure with mid-range ejection fraction; HF<sub>r</sub>EF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association heart failure classification; PROM, Predicted Risk Of Mortality; STS, Society of Thoracic Surgeons; SYNTAX, Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery; TIA, transient ischaemic attack.

<sup>a</sup>Medically treated.

<sup>b</sup>Within 7 days of randomization.

<sup>c</sup>Estimated glomerular filtration rate < 60 mL/min.

<sup>d</sup>World Health Organization criteria: Hematocrit < 13 g/dL (male) and < 12 g/dL (female).

<sup>e</sup>Ventricular tachycardia, ventricular fibrillation, or aborted sudden death; preoperative cardiac massage; preoperative ventilation before anesthetic room; preoperative inotropes or intra-aortic balloon pump; preoperative acute renal failure (anuria or oliguria < 10 mL/h).

**Table 2** Procedural characteristics and discharge medication according to left ventricular ejection fraction and revascularization assignment

|                                       | CABG (n = 911)                           |  |                               | P-value | PCI (n = 893)                            |  |                               | P-value |
|---------------------------------------|--|--|-------------------------------|---------|--|--|-------------------------------|---------|
|                                       | LVEF <40% (HF <sub>Fr</sub> EF) (n = 31) | LVEF 40–49% (HF <sub>mr</sub> EF) (n = 84) | Preserved LVEF ≥50% (n = 796) |         | LVEF <40% (HF <sub>Fr</sub> EF) (n = 43) | LVEF 40–49% (HF <sub>mr</sub> EF) (n = 68) | Preserved LVEF ≥50% (n = 782) |         |
| Assigned treatment received           | 28/31 (90.3)                             | 81/84 (96.4)                               | 774/796 (97.2)                | 0.098   | 42/43 (97.7)                             | 66/68 (97.1)                               | 773/782 (98.9)                | 0.22    |
| Procedure duration <sup>a</sup> (min) | 231 [215–305]                            | 239 [200–291]                              | 235 [195–280]                 | 0.39    | 66 [51–101]                              | 83 [65–109]                                | 73 [51–106]                   | 0.59    |
| Bypass time (min)                     | 80 [59–87]                               | 73 [62–94]                                 | 74 [57–97]                    | 0.77    | –  | –  | –                             | –       |
| Off-pump CABG                         | 10/28 (35.7)                             | 23/81 (28.4)                               | 225/774 (29.1)                | 0.74    | –  | –  | –                             | –       |
| BITAs used                            | 4/28 (14.3)                              | 25/80 (31.3)                               | 219/771 (28.4)                | 0.22    | –  | –  | –                             | –       |
| No. of distal anastomoses             | 2.5 ± 0.6                                | 2.6 ± 0.8                                  | 2.7 ± 0.8                     | 0.83    | –  | –  | –                             | –       |
| No. of grafts used                    | 3.0 [2.0–3.0]                            | 2.0 [2.0–3.0]                              | 2.0 [2.0–3.0]                 | 0.32    | –  | –  | –                             | –       |
| No. of stents implanted               | –  | –  | –                             | –       | 2.0 [1.0–4.0]                            | 3.0 [2.0–3.0]                              | 2.0 [1.0–3.0]                 | 0.004   |
| Total stent length (mm)               | –  | –  | –                             | –       | 35.0 [26.0–76.0]                         | 52.0 [30.0–84.0]                           | 38.0 [23.0–61.0]              | 0.003   |
| Intubation > 48 h                     | 2/29 (6.9)                               | 5/82 (6.1)                                 | 21/787 (2.7)                  | 0.12    | 1/42 (2.4)                               | 0/67 (0.0)                                 | 3/778 (0.4)                   | 0.15    |
| Renal failure <sup>b</sup>            | 4/29 (13.8)                              | 4/82 (4.9)                                 | 15/787 (1.9)                  | 0.001   | 2/42 (4.8)                               | 0/67 (0.0)                                 | 4/778 (0.5)                   | 0.004   |
| Major arrhythmia                      | 9/29 (31.0)                              | 17/82 (20.7)                               | 108/787 (13.7)                | 0.011   | 1/42 (2.4)                               | 1/67 (1.5)                                 | 14/778 (1.8)                  | 0.94    |
| Post-operative hospital stay (days)   | 9.0 [5.0–13.0]                           | 7.0 [5.0–10.0]                             | 6.0 [5.0–9.0]                 | 0.02    | 1.5 [1.0–3.0]                            | 2.0 [1.0–3.0]                              | 1.0 [1.0–2.0]                 | 0.20    |
| Discharge medications                 |  |  |                               |         |  |  |                               |         |
| Aspirin                               | 26/27 (96.3)                             | 79/79 (100.0)                              | 752/760 (98.9)                | 0.26    | 42/42 (100.0)                            | 66/66 (100.0)                              | 760/766 (99.2)                | 0.65    |
| P2Y <sub>12</sub> inhibitor           | 7/27 (25.9)                              | 22/79 (27.8)                               | 259/765 (33.9)                | 0.40    | 42/42 (100.0)                            | 65/66 (98.5)                               | 754/769 (98.0)                | 0.64    |
| DAPT                                  | 7/27 (25.9)                              | 22/79 (27.8)                               | 254/765 (33.2)                | 0.48    | 42/42 (100.0)                            | 65/66 (98.5)                               | 748/769 (97.3)                | 0.47    |
| Statin                                | 25/27 (92.6)                             | 70/79 (88.6)                               | 709/765 (92.7)                | 0.43    | 40/42 (95.2)                             | 66/66 (100.0)                              | 741/769 (96.4)                | 0.26    |
| Beta-blocker                          | 26/27 (96.3)                             | 74/79 (93.7)                               | 704/765 (92.0)                | 0.64    | 40/42 (95.2)                             | 57/66 (86.4)                               | 634/769 (82.4)                | 0.08    |
| ACE-inhibitor or ARB                  | 12/27 (44.4)                             | 37/79 (46.8)                               | 311/765 (40.7)                | 0.54    | 26/42 (61.9)                             | 39/66 (59.1)                               | 428/769 (55.7)                | 0.65    |
| Calcium-channel blockers              | 0/27 (0.0)                               | 9/79 (11.4)                                | 53/765 (6.9)                  | 0.12    | 0/42 (0.0)                               | 1/66 (1.5)                                 | 48/769 (6.2)                  | 0.07    |
| Diuretics                             | 7/27 (25.9)                              | 18/79 (22.8)                               | 185/765 (24.2)                | 0.94    | 2/42 (4.8)                               | 2/66 (3.0)                                 | 26/769 (3.4)                  | 0.88    |

Values are n (%), median [interquartile range], or mean ± standard deviation.

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; BITA, bilateral internal thoracic artery; CABG, coronary artery bypass grafting; DAPT, dual antiplatelet therapy; HF<sub>Fr</sub>EF, heart failure with mid-range ejection fraction; HF<sub>mr</sub>EF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.

<sup>a</sup>Time from start of anaesthesia to procedure end (e.g. for CABG this is the time of skin closure).

<sup>b</sup>Serum creatinine increase by ≥1 mg/dL from baseline or need for dialysis.

LVEF (37.5% vs. 21.5% vs. 23.8%, respectively;  $P = 0.02$ ). The specific cardiovascular risk profile of patients with HF<sub>Fr</sub>EF, HF<sub>mr</sub>EF and preserved LVEF randomized to PCI vs. CABG are reported in online supplementary Table S1. No differences between baseline characteristics among those patients with vs. those without known baseline LVEF were identified (online supplementary Table S2).

## Procedural characteristics

Surgical techniques used for CABG were similar among patients with HF<sub>Fr</sub>EF, HF<sub>mr</sub>EF and preserved LVEF (Table 2). Off-pump CABG was performed in 35.7% of patients ( $n = 10/28$ ) with HF<sub>Fr</sub>EF, in 28.4% of patients ( $n = 23/81$ ) with HF<sub>mr</sub>EF and in 29.1% of patients ( $n = 225/774$ ) with preserved LVEF. Bilateral internal thoracic arteries were used less frequently in patients with HF<sub>Fr</sub>EF (14.3%;  $n = 4/28$ ) vs. in those with HF<sub>mr</sub>EF (31.3%;  $n = 25/80$ ) and preserved LVEF (28.4%;  $n = 219/771$ ). The number of distal anastomoses did not differ among patients with HF<sub>Fr</sub>EF, HF<sub>mr</sub>EF and preserved LVEF. The duration of the PCI procedure was similar among patients with HF<sub>Fr</sub>EF, HF<sub>mr</sub>EF and preserved LVEF (Table 2), while the number of implanted stents and the total stent length differed significantly between patients with HF<sub>Fr</sub>EF, HF<sub>mr</sub>EF and preserved LVEF.

After CABG, patients with HF<sub>Fr</sub>EF vs. HF<sub>mr</sub>EF vs. preserved LVEF had a longer post-operative hospital stay (median 9.0 vs. 7.0 vs. 6.0,  $P = 0.02$ ), and more often experienced renal failure and


arrhythmias (Table 2). Following PCI, no differences were identified in hospital stay, however patients with HF<sub>Fr</sub>EF more often had post-operative renal failure. No statistical differences were noted in medical treatment at the time of discharge after CABG or PCI according to LVEF status.

## Thirty-day outcomes

Overall, the event rates for the primary endpoint, as well as for the individual endpoints, were relatively low. The composite endpoint of death, stroke, or MI occurred more frequently in patients with preserved LVEF that underwent CABG compared with those that underwent PCI (7.9% vs. 5.1%; HR 0.65, 95% CI 0.44–0.97; online supplementary Table S3). No treatment-by-subgroup interaction was identified between LVEF status (HF<sub>Fr</sub>EF, HF<sub>mr</sub>EF and preserved LVEF) and revascularization strategy (PCI vs. CABG) among any of the clinical endpoints.

## Three-year outcomes

The composite of death, stroke, or MI was 28.3% vs. 15.7% vs. 14.5% according to HF<sub>Fr</sub>EF, HF<sub>mr</sub>EF and preserved LVEF status ( $P = 0.02$ ) (Figure 1A). All-cause death occurred in 19.5% vs. 9.6% vs. 6.2%, respectively ( $P < 0.001$ ) (Figure 1B). Smoothing spline analysis showed a gradually increasing risk of all-cause death with decreasing LVEF below 50% after PCI (Figure 2) (HR 1.15, 95% CI



0.95–1.39) and CABG (HR 1.90, 95% CI 1.05–3.43). Patients with HFrEF, HFmrEF and preserved LVEF had comparable rates of stroke and MI (Figure 1C and D).

The rates of the 3-year composite primary endpoint were similar between PCI and CABG across groups of patients with HFrEF (29.3% after PCI vs. 27.6% after CABG:  $P=0.90$ ), those with HFmrEF (16.2% vs. 15.0%;  $P=0.93$ ) and preserved LVEF (14.5% vs. 14.6%;  $P=0.95$ ) (Table 3 and Figure 3). The individual rates of all-cause death, stroke, MI and ischaemia-driven revascularization were not statistically different between PCI and CABG in patients with HFrEF or HFmrEF. Any repeat revascularization occurred more often after PCI vs. CABG in those patients with preserved LVEF (HR 1.68, 95% CI 1.22–2.30), driven by increased rates of ischaemia-driven revascularization. No treatment-by-subgroup interaction existed according to baseline LVEF and revascularization strategy. Adjusted outcomes from the

full multivariable adjusted Cox proportional hazard model were similar to unadjusted outcomes (Table 3).

## Discussion

In the current pre-specified sub-study from the EXEL trial, the largest randomized study to date comparing PCI vs. CABG in selected patients with LMCAD, the composite rate of death, stroke, or MI at 3-year follow-up was significantly higher in patients with impaired (<50%;  $n=74$ ) vs. preserved LVEF ( $\geq 50%$ ;  $n=1730$ ), driven by an increased rate of all-cause death in those with HFrEF ( $n=74$ , LVEF<40%). Mortality furthermore progressively increased with decreasing LVEF. Nonetheless, baseline LVEF did not influence the relative 30-day or 3-year treatment outcomes in patients with LMCAD randomly allocated to PCI vs. CABG. Since data on the influence of HFrEF and HFmrEF on



**Table 3** Three-year unadjusted and adjusted clinical outcomes stratified according to left ventricular ejection fraction status and revascularization strategy


| Clinical outcomes                  | PCI frequency, n (%) | CABG frequency, n (%) | Unadjusted HR (95% CI), P-value | P <sub>interaction</sub> | Adjusted HR (95% CI) |
|------------------------------------|----------------------|-----------------------|---------------------------------|--------------------------|----------------------|
| Death, stroke or MI                |                      |                       |                                 |                          |                      |
| HF <sub>r</sub> EF                 | 11 (29.3)            | 8 (27.6)              | 1.04 (0.46–2.35), 0.90          | 0.90                     | 1.05 (0.42–2.61)     |
| HF <sub>m</sub> rEF                | 11 (16.2)            | 12 (15.0)             | 0.96 (0.38–2.38), 0.92          |                          | 1.06 (0.40–2.80)     |
| Preserved LVEF                     | 113 (14.6)           | 113 (14.5)            | 0.99 (0.76–1.28), 0.89          |                          | 1.05 (0.79–1.38)     |
| Death, stroke, MI or IDR           |                      |                       |                                 |                          |                      |
| HF <sub>r</sub> EF                 | 12 (31.9)            | 9 (31.0)              | 1.22 (0.59–2.52), 0.82          | 0.78                     | 1.18 (0.53–2.66)     |
| HF <sub>m</sub> rEF                | 15 (22.1)            | 14 (17.4)             | 0.92 (0.39–2.19), 0.59          |                          | 1.03 (0.41–2.56)     |
| Preserved LVEF                     | 173 (22.4)           | 147 (18.9)            | 1.18 (0.95–1.47), 0.16          |                          | 1.24 (0.98–1.56)     |
| All-cause death                    |                      |                       |                                 |                          |                      |
| HF <sub>r</sub> EF                 | 7 (18.6)             | 6 (20.7)              | 0.63 (0.21–1.87), 0.78          | 0.20                     | 0.53 (0.16–1.81)     |
| HF <sub>m</sub> rEF                | 5 (7.4)              | 9 (11.5)              | 0.85 (0.29–2.54), 0.40          |                          | 0.77 (0.23–2.55)     |
| Preserved LVEF                     | 57 (7.4)             | 39 (5.0)              | 1.47 (0.98–2.20), 0.08          |                          | 1.50 (0.98–2.31)     |
| Cardiovascular death               |                      |                       |                                 |                          |                      |
| HF <sub>r</sub> EF                 | 5 (13.5)             | 5 (17.8)              | 0.38 (0.08–1.88), 0.62          | 0.26                     | 0.15 (0.02–1.28)     |
| HF <sub>m</sub> rEF                | 2 (3.0)              | 6 (7.8)               | 0.73 (0.21–2.51), 0.22          |                          | 0.70 (0.18–2.81)     |
| Preserved LVEF                     | 29 (3.8)             | 23 (3.0)              | 1.27 (0.73–2.19), 0.40          |                          | 1.40 (0.79–2.48)     |
| Stroke                             |                      |                       |                                 |                          |                      |
| HF <sub>r</sub> EF                 | 2 (5.5)              | 1 (4.2)               | 0.75 (0.13–4.49), 0.74          | 0.49                     | 1.43 (0.19–10.69)    |
| HF <sub>m</sub> rEF                | 2 (3.0)              | 3 (3.8)               | 1.49 (0.13–16.39), 0.77         |                          | -                    |
| Preserved LVEF                     | 14 (1.9)             | 23 (3.0)              | 0.61 (0.31–1.19), 0.14          |                          | 0.67 (0.34–1.32)     |
| MI                                 |                      |                       |                                 |                          |                      |
| HF <sub>r</sub> EF                 | 3 (8.9)              | 3 (10.3)              | 1.00 (0.34–2.97), 0.62          | 0.78                     | 0.95 (0.29–3.19)     |
| HF <sub>m</sub> rEF                | 6 (9.0)              | 7 (8.7)               | 0.69 (0.14–3.41), 0.99          |                          | 1.02 (0.17–6.29)     |
| Preserved LVEF                     | 62 (8.1)             | 65 (8.4)              | 0.95 (0.67–1.35), 0.79          |                          | 0.99 (0.69–1.44)     |
| Repeat revascularization, any      |                      |                       |                                 |                          |                      |
| HF <sub>r</sub> EF                 | 4 (11.9)             | 2 (7.5)               | 2.30 (0.58–9.19), 0.68          | 0.96                     | 1.91 (0.45–8.10)     |
| HF <sub>m</sub> rEF                | 6 (9.3)              | 3 (3.8)               | 1.43 (0.26–7.82), 0.37          |                          | 2.77 (0.31–25.02)    |
| Preserved LVEF                     | 100 (13.2)           | 61 (8.1)              | 1.68 (1.22–2.30), 0.001         |                          | 1.72 (1.23–2.39)     |
| Ischaemia-driven revascularization |                      |                       |                                 |                          |                      |
| HF <sub>r</sub> EF                 | 4 (11.9)             | 2 (7.5)               | 2.30 (0.57–9.18), 0.68          | 0.95                     | 1.86 (0.44–7.88)     |
| HF <sub>m</sub> rEF                | 6 (9.3)              | 3 (3.8)               | 1.43 (0.26–7.82), 0.37          |                          | 2.82 (0.31–25.56)    |
| Preserved LVEF                     | 98 (12.9)            | 60 (8.0)              | 1.67 (1.21–2.30), 0.002         |                          | 1.72 (1.23–2.40)     |

CABG, coronary artery bypass grafting; CI, confidence interval; HF<sub>m</sub>rEF, heart failure with mid-range ejection fraction; HF<sub>r</sub>EF, heart failure with reduced ejection fraction; HR, hazard ratio; IDR, ischaemia-driven revascularization; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention. The event rates are Kaplan–Meier estimates (n events) with unadjusted and adjusted HR and 95% CI. A full multivariable Cox proportional hazards model using was constructed to provide adjusted outcomes for the primary and secondary endpoints. Significance levels of 0.10 for both addition and removal from the model were used. Adjusted models include the following covariates: age, sex (female), body mass index >30 kg/m<sup>2</sup>, medically treated hypertension, hyperlipidaemia and diabetes, history of MI, history of stroke or transient ischaemic attack, peripheral vascular disease, carotid artery disease, chronic obstructive pulmonary disease, creatinine >200 μmol/L, recent MI, history of anaemia, diffuse or small vessel disease, LVEF (as continuous variable), unstable angina, SYNTAX score (as continuous variable), New York Heart Association class < II, and revascularization strategy (PCI vs. CABG).


clinical outcomes after PCI and CABG are limited, especially in those patients with left main disease, a strength of the present study is that it provides important insights into clinical outcomes during 3-year follow-up in this high-risk patient population. These insights can aid clinical decision making in determining the optimal treatment strategy in such a specific patient population requiring revascularization.

In the overall cohort, patients with HF<sub>r</sub>EF or HF<sub>m</sub>rEF had a significantly more complex cardiovascular risk profile, compared with those with preserved LVEF. The detrimental cardiovascular risk profile especially in patients with HF<sub>r</sub>EF and LMCAD, in concert with less viable myocardium, likely drives the increased all-cause

death rate in this specific subgroup.<sup>12,13</sup> While no significant interactions were noted between clinical outcomes 3 years after PCI and CABG as a function of LVEF, patients with impaired LVEF (HF<sub>r</sub>EF and HF<sub>m</sub>rEF) experienced a longer post-operative hospital stay after CABG due to more frequent post-operative arrhythmias and renal failure. In contrast, post-PCI complications and length of stay were not significantly increased in patients with impaired LVEF. The clinical outcomes in patients with HF<sub>m</sub>rEF were essentially similar to the outcomes in patients with preserved LVEF; findings that contribute to the better understanding of the impact of heart failure and the preferred treatment modalities in those patients with LMCAD and LVEF 40–49% and >50%.<sup>14,15</sup> Moreover,



**Figure 2** The influence of Left Ventricular Ejection Fraction (LVEF) on all-cause death at 3 years in patients undergoing left main coronary artery revascularization by either Percutaneous Coronary Intervention (PCI) versus Coronary Artery Bypass Grafting (CABG). CI, confidence interval.



**Figure 3** Three-year primary endpoint after percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with heart failure with reduced, mid-range and preserved left ventricular ejection fraction (LVEF). Kaplan–Meier estimates of the composite primary endpoint of all-cause death, stroke, or myocardial infarction (MI) after PCI vs. CABG in patients with heart failure with reduced (A), mid-range (B) and preserved LVEF (C). *P*-values were generated by the log-rank test. CI, confidence interval; HR, hazard ratio.

all peri-procedural outcomes should be considered along with the potential short- and long-term clinical benefits of both revascularization strategies in patients with impaired LVEF during structured multidisciplinary heart team meetings.

No treatment interactions were observed between PCI and CABG according to baseline LVEF status for 3-year outcomes. Nonetheless, impaired LVEF (<50%) was strongly associated with 3-year all-cause death in the overall cohort. To date, conflicting evidence has been published on the preferred revascularization modality in patients with CAD and impaired LVEF, with limited randomized data to provide guidance. The observational CREDO-Kyoto PCI/CABG Registry Cohort 2 (LVEF ≤50% vs. LVEF >50%) reported that PCI in patients with impaired LVEF was associated with higher rates of all-cause death after 5 years compared to CABG (33.2% vs. 23.4%;  $P < 0.01$ ).<sup>16</sup> The observational, propensity-matched analysis by Nagendran *et al.*<sup>17</sup> ( $n = 1738$ )

showed lower rates of major adverse cardiac and cerebrovascular events and improved 5-year survival with CABG compared with PCI in patients with diabetes and impaired LVEF (35–49% and <35%). Nonetheless, the largest pooled analysis of individual patient-level data from 11 randomized trials found no interaction for mortality between treatment strategy (PCI vs. CABG) and different LVEF cut-off values (<30%, 30–49% and ≥50%;  $P_{\text{interaction}} = 0.65$ ).<sup>18</sup>

Finally, in the present study the rate of the composite of death, stroke, or MI at 3 years was significantly higher in patients with HFrEF (28.3%) compared with those patients with HFmrEF (15.7%) or preserved LVEF (14.5%) ( $P = 0.02$ ) (Figure 1A). This finding was driven by an increased rate of all-cause death and cardiovascular death in those patients whom are at higher-risk for adverse events (e.g. patients with HFrEF). Moreover, in a smoothing spline analysis, the risk of mortality continued to increase when LVEF decreased

below 50%. Nonetheless, no significant differences in clinical outcomes were found between CABG or PCI in patients with LVEF <40% at 3-year follow-up. The propensity-matched analysis by Shah et al.<sup>19</sup> ( $n = 134$ ) reported that patients with coronary artery disease and LVEF <30% experienced an increased risk of mortality when undergoing PCI vs. CABG at 8-year follow-up (multivariable adjusted HR 3.29, 95% CI 1.78–6.10;  $P < 0.001$ ). However, only 32% of patients in the study by Shah et al. had LMCAD, with the majority having three-vessel disease. Longer-term follow-up from the EXCEL trial is required to determine if differences in survival between the PCI and CABG groups might emerge over time.

## Limitations

Although the present analysis was pre-specified, the number of patients with impaired LVEF was modest, especially those with HF<sub>r</sub>EF ( $n = 74$ ), limiting statistical interaction testing. Furthermore, the EXCEL trial excluded patients with high site-assessed SYNTAX scores (>32), and thus the present results might not apply to the particularly high-risk group with more complex CAD in whom CABG is considered standard of care. Finally, patient follow-up in the EXCEL trial is prolonged up to 5 years; however, even this follow-up duration may not be long enough to determine a potential benefit of either revascularization strategy.

## Conclusions

At 3-year follow-up in the EXCEL trial, the composite rate of death, stroke, or MI was significantly higher in patients with HF<sub>r</sub>EF compared with HF<sub>m</sub>rEF or preserved LVEF, driven by an increased rate of all-cause death. No significant differences in clinical outcomes after PCI vs. CABG were observed among patients with HF<sub>r</sub>EF, HF<sub>m</sub>rEF and preserved LVEF. Prolonged follow-up could provide important insights on differences in clinical outcomes that might emerge over time.

## Supplementary Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Table S1.** Baseline characteristics according to left ventricular ejection fraction and revascularization assignment

**Table S2.** Baseline characteristics for those patients with versus without known baseline LVEF

**Table S3.** Thirty-day clinical outcomes according to left ventricular ejection fraction and revascularization assignment

## Funding

This study was supported by Abbott Vascular, Santa Clara, CA, USA.

**Conflict of interest:** J.D.P.: consultant – Medtronic. P.W.S.: consultant – Abbott, Biosensors, Medtronic, Micell Technologies, SINOMED, Philips/Volcano, Xeltis, HeartFlow. J.F.S.: consultant – Medtronic, Edwards, and Sorin. Advisory board – Medtronic Cardiac Surgery. S.J.H.: employee – Medtronic. A.P.K.: employee –

Medtronic. The other authors declare to have no conflicts of interest.

## References

- Sousa-Uva M, Neumann FJ, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J-P, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferović PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur J Cardiothorac Surg* 2019;**55**:4–90.
- Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, Fonarow GC, Lange RA, Levine GN, Maddox TM, Naidu SS, Ohman EM, Smith PK. 2014 ACC/AHA/AAATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol* 2014;**64**:1929–1949.
- Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne-Nickens P, Sopko G, Rouleau JL; STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. *N Engl J Med* 2016;**374**:1511–1520.
- Wolff G, Dimitroulis D, Andreotti F, Kolodziejczak M, Jung C, Scicchitano P, Devito F, Zito A, Occhipinti M, Castiglioni B, Calveri G, Maisano F, Ciccone MM, De Servi S, Navarese EP. Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis. *Circ Heart Fail* 2017;**10**:e003255.
- Capodanno D, Stone GW, Morice MC, Bass TA, Tamburino C. Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data. *J Am Coll Cardiol* 2011;**58**:1426–1432.
- Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR, Choi JW, Ruzyllo W, Religa G, Huang J, Roy K, Dawkins KD, Mohr F. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. *Circulation* 2014;**129**:2388–2394.
- Cavalcante R, Sotomi Y, Lee CW, Ahn JM, Farooq V, Tateishi H, Tenekecioglu E, Zeng Y, Suwannasom P, Collet C, Albuquerque FN, Onuma Y, Park SJ, Serruys PW. Outcomes after percutaneous coronary intervention or bypass surgery in patients with unprotected left main disease. *J Am Coll Cardiol* 2016;**68**:999–1009.
- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruijloep LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016;**18**:891–975.
- Kappetein AP, Serruys PW, Sabik JF, Leon MB, Taggart DP, Morice MC, Gersh BJ, Pocock SJ, Cohen DJ, Wallentin L, Ben-Yehuda O, van Es GA, Simonton CA, Stone GW. Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. *EuroIntervention* 2016;**12**:861–872.
- Stone GW, Sabik JF, Serruys PW, Simonton CA, Genereux P, Puskas J, Kandzari DE, Morice MC, Lembo N, Brown WM 3rd, Taggart DP, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogats G, Mansour S, Noiseux N, Sabate M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, Schampaert E, Page P, Dressler O, Kosmidou I, Mehran R, Pocock SJ, Kappetein AP; EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. *N Engl J Med* 2016;**375**:2223–2235.
- Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). *J Am Coll Cardiol* 2013;**62**:1563–1570.
- Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozd J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA; STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. *N Engl J Med* 2011;**364**:1617–1625.



13. Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, Portnay EL, Marshalko SJ, Radford MJ, Krumholz HM. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. *J Am Coll Cardiol* 2003;**42**:736–742.
14. Nauta JF, Hummel YM, van Melle JP, van der Meer P, Lam CS, Ponikowski P, Voors AA. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? *Eur J Heart Fail* 2017;**19**:1569–1573.
15. Solomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Dungen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med* 2019;**381**:1609–1620.
16. Marui A, Kimura T, Nishiwaki N, Mitsudo K, Komiya T, Hanyu M, Shiomi H, Tanaka S, Sakata R. Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions  $\leq 50\%$  versus  $>50\%$  (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). *Am J Cardiol* 2014;**114**:988–996.
17. Nagendran J, Bozso SJ, Norris CM, McAlister FA, Appoo JJ, Moon MC, Freed DH, Nagendran J. Coronary artery bypass surgery improves outcomes in patients with diabetes and left ventricular dysfunction. *J Am Coll Cardiol* 2018;**71**:819–827.
18. Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, Domanski MJ, Farkouh ME, Flather M, Fuster V, Hlatky MA, Holm NR, Hueb WA, Kamalesh M, Kim YH, Makikallio T, Mohr FW, Papageorgiou G, Park SJ, Rodriguez AE, Sabik JF 3rd, Stables RH, Stone GW, Serruys PW, Kappetein AP. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. *Lancet* 2018;**391**:939–948.
19. Shah S, Benedetto U, Caputo M, Angelini GD, Vohra HA. Comparison of the survival between coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with poor left ventricular function (ejection fraction  $<30\%$ ): a propensity-matched analysis. *Eur J Cardiothorac Surg* 2019;**55**:238–246.